uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
In-vivo characterization of innate and adaptive immune responses following injection with vaccine antigen and saponin-based adjuvants
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Novavax AB.
2017 (English)Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Modern vaccines are usually formulated of recombinant pathogen-derived antigens, however these are in themselves poorly immunogenic, thus often requiring co-formulation with an adjuvant to enhance the immune response. Due to poor immunogenicity of the available adjuvants, there is a growing need for the development of new candidates, one of which is the saponin-based Matrix-M™ adjuvant. The main aim of this study was to compare the immune enhancement of Matrix-M™ adjuvant, with or without antigen, to other saponin-based adjuvants. First, the immunogenicity of a heat-degraded or intact Matrix-M™ adjuvant was compared to evaluate the stability. These were also compared to another saponin-based adjuvant, Adjuvant X. The intact Matrix-M™ adjuvant induced more IL-2 secreting T-cells compared to the degraded product, and Matrix-M™ adjuvant induced a stronger T-cell response than Adjuvant X. Therefore, the early cell recruitment to the dLN was characterized following injection with Matrix-M™ adjuvant, Adjuvant X or Adjuvant Y. After 48 hours, Matrix-M™ adjuvant activated immune cells more efficiently than the two other adjuvants. In addition, we compared the early cell recruitment to dLN induced by four different influenza vaccine formulations; soluble recombinant hemagglutinin protein antigen on its own or incorporated into a recombinant MVA vector, both formulated with or without Matrix-M™ adjuvant. After 48 hours, the vaccine formulations containing Matrix-M™ adjuvant induced significantly higher proportions of activated cells among all investigated cell populations. In conclusion, Matrix-M™ adjuvant efficiently promoted the recruitment and activation of innate and adaptive immune cells, both with and without antigen.  

Place, publisher, year, edition, pages
2017. , 26 p.
Keyword [en]
Adjuvant, vaccine, Matrix-M™ adjuvant, influenza
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:uu:diva-326192OAI: oai:DiVA.org:uu-326192DiVA: diva2:1119351
Educational program
Master Programme in Infection Biology
Supervisors
Examiners
Available from: 2017-11-02 Created: 2017-07-04 Last updated: 2017-11-02Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Medical Biochemistry and Microbiology
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 7 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf